Associated Papers
Diversity of BRAF mutations in non-small cell lung cancer and implications on treatment.
Lu K et al.
Npj Precision Oncology, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database.
Menzer C et al.
European Journal of Cancer (oxford, England : 1990), 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.
Bossé Y et al.
Lung Cancer (amsterdam, Netherlands), 2025
Spontaneous Necrosis of a High-Risk Bladder Tumor Under Immunotherapy for Concurrent Malignant Melanoma: Role of BRAF Mutations and PD-L1 Expression.
Condoiu C et al.
Biomedicines, 2025
BRAF Deletion in Adult Patients with Langerhans Cell Histiocytosis Correlates with Multisystem Disease and Poor Outcomes.
Lang M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Targeting BRAF in cancers - from molecular diagnostics to personalized therapy.
Pyc Z et al.
Biotechnologia, 2025
Exploiting BRAF mutations in the therapeutic approach towards oral and maxillofacial tumors.
Yi JR et al.
Journal of Stomatology, Oral and Maxillofacial Surgery, 2024
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.
Wallen ZD et al.
Frontiers in Oncology, 2024
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
The Genomic Landscape of Melanoma and Its Therapeutic Implications.
Yang TT et al.
Genes, 2023
Targeted next-generation sequencing of EUS-guided through-the-needle-biopsy sampling from pancreatic cystic lesions.
Rift CV et al.
Gastrointestinal Endoscopy, 2023
Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.
Bhai P et al.
Frontiers in Oncology, 2023
Ongoing progress in BRAF-mutated non-small cell lung cancer.
Abdayem P et al.
Clinical Advances in Hematology & Oncology : H&o, 2022
Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors.
Mullaguri SC et al.
Toxicology and Applied Pharmacology, 2022
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
Riudavets M et al.
Lung Cancer (amsterdam, Netherlands), 2022
Targeted Therapy for Melanomas Without BRAF V600 Mutations.
Menzer C et al.
Current Treatment Options in Oncology, 2022
Systematic review and meta-analysis of genomic alterations in acral melanoma.
Broit N et al.
Pigment Cell & Melanoma Research, 2022
Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation.
Wang M et al.
Journal for Immunotherapy of Cancer, 2022
Altered Signaling Pathways Revealed by Comprehensive Genomic Profiling in Patients With Unknown Primary Tumors.
Yang Z et al.
Frontiers in Oncology, 2022
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens.
Cheng LY et al.
Scientific Reports, 2021
Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.
Owsley J et al.
Experimental Biology and Medicine (maywood, N.j.), 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer.
Costigan DC et al.
Genes, Chromosomes & Cancer, 2020
The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients.
Lin Q et al.
Journal of Translational Medicine, 2019
An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer.
Haynes BC et al.
Translational Oncology, 2019
RAS Mutation in Mucinous Carcinoma of the Ovary
Panyavaranant P et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2019
Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.
Pires da Silva I et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer: Results of a 2-Year Experience on 1343 Samples.
Legras A et al.
The Journal of Molecular Diagnostics : Jmd, 2018
KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature.
Chen F et al.
Oncology Letters, 2018
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients.
Richtig G et al.
The British Journal of Dermatology, 2017
Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
Xing D et al.
Human Pathology, 2017
Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
Malgulwar PB et al.
Journal of Neuro-oncology, 2017
Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay.
Bidshahri R et al.
The Journal of Molecular Diagnostics : Jmd, 2016
The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF.
Kiel C et al.
Elife, 2016
Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
de Leng WW et al.
Plos One, 2016
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Lee JY et al.
Oncotarget, 2015
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.
Park K et al.
Oncotarget, 2015
Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique.
Kriegsmann M et al.
Diagnostic Pathology, 2015
Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
Sakai K et al.
Plos One, 2015
The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients.
Yang LB et al.
International Journal of Endocrinology, 2015
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
MacConaill LE et al.
The Journal of Molecular Diagnostics : Jmd, 2014
Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
Bisht S et al.
Medical Oncology (northwood, London, England), 2014
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
Brastianos PK et al.
Nature Genetics, 2014